HRTX CEO converts 13,797 RSUs; post-trade holding 488,335 shares
Heron Therapeutics (HRTX) reported an insider equity change by CEO and Director Craig Collard.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Heron Therapeutics (HRTX) reported an insider equity change by CEO and Director Craig Collard. On 10/19/2025, 13,797 restricted stock units (RSUs) were converted to common stock via transaction code M, resulting in the acquisition of 13,797 shares at $0 per RSU. Following the transaction, 488,335 common shares were beneficially owned directly. The filing notes the RSUs vest in 16 equal quarterly installments beginning one quarter after 01/19/2024. After this event, 124,172 RSUs were directly held.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 13,797 | $0.00 | $0.00 |
| Exercise | Common Stock | 13,797 | $0.00 | $0.00 |
Footnotes (2)
- F1. Each restricted stock unit represents a contingent right to receive one share of common stock.
- F2. The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did HRTX (Heron Therapeutics) disclose in this Form 4?
What RSU balance remains for the HRTX CEO?
What is the vesting schedule of the RSUs in the HRTX Form 4?
What was the price per RSU for the conversion?
What does transaction code M indicate in the Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.